Three Late-Stage Trials Support Novartis COPD Drug’s Efficacy

Novartis’ inhaled once-daily drug for chronic obstructive pulmonary disease (COPD), QVA149, met its primary endpoints in its first three Phase III trials, the Swiss-owned drugmaker says. The trials for QVA149, an inhaled combination product that would pair NVA237 (glycopyrronium bromide), a long-acting muscarinic antagonist, with long-acting beta2-agonist (LABA) indacaterol, are components of the IGNITE program. Novartis says IGNITE is one of the largest international patient registration programs for COPD, comprising 10 studies in total.
Washington Drug Letter